Pycnogenol is a standardized French maritime pine bark extract studied mainly for vessel lining function, leg venous symptoms, knee joint comfort, and modest shifts in blood sugar, weight, and cholesterol markers. Trials report small average improvements, but evidence certainty for most chronic conditions is very low. A relatively low-risk lifestyle add-on—not a proven lifespan therapy. (Full Review)

Protocol

Standard dose

100–200 mg/day

Branded Pycnogenol or equivalently standardized French maritime pine bark extract

Split dosing

2 doses with meals

Breakfast and evening meal preferred; improves gastrointestinal tolerability

Evaluation window

Multi-week

Clinical vascular effects build over days to weeks—not single-dose expectations

Time to effect

Endothelial / vascular

Days to weeks

Platelet and vessel-lining function signals can appear early

Venous & joint symptoms

2–12 weeks

Leg swelling, heaviness, and joint comfort need multi-week windows

Benefits

Medium: Improved endothelial function; Reduced symptoms of chronic venous insufficiency; Knee osteoarthritis symptom relief; Modest cardiometabolic marker improvements

Low: Working memory support in older adults; Skin photoprotection and elasticity support; Erectile function

Speculative: Systemic longevity or disease-span extension

Contraindications

Known allergy to pine bark or product excipients

First-trimester pregnancy

Breastfeeding

Children under typical studied ages for a given indication without specialist oversight

Active major bleeding or immediately pre-/post-major surgery without clinician approval

Key Interactions

Anticoagulants and antiplatelet agents (warfarin, apixaban, clopidogrel, aspirin)

Antihypertensive drugs (ACE inhibitors such as lisinopril, ARBs such as losartan, calcium-channel blockers, beta-blockers)

Glucose-lowering agents (metformin, SGLT2 inhibitors such as empagliflozin, insulin, sulfonylureas)

NSAIDs (ibuprofen, naproxen)

Other polyphenol-rich extracts (grape seed OPCs, high-dose green tea catechins)

L-arginine / citrulline

Immunosuppressants / chemotherapy

Risk & Side Effects

Medium: Gastrointestinal discomfort

Low: Dizziness, headache, or transient lightheadedness; Dermatologic reactions

Speculative: Additive bleeding tendency; Excessive glucose or blood-pressure lowering in sensitive users

Monitoring

Marker	Target	Why
Resting blood pressure	Often near <120/80 mmHg for optimized adults (individualize)	Tracks possible BP shift and safety with antihypertensives
Fasting glucose	Often ~70–90 mg/dL functional aim	Detects additive glucose lowering
HbA1c	Functional aims often ~5.0–5.4% if no hypoglycemia risk	3-month glycemic exposure
LDL cholesterol	Functional targets commonly <100 mg/dL (stricter if high risk)	Cardiometabolic surrogate in meta-analyses
hs-CRP	Often <1.0 mg/L as lower-inflammation aim	Optional inflammation context
Symptom score (pain VAS or WOMAC / venous score)	Improvement vs personal baseline	Primary effectiveness for joint/venous goals

Cadence: Recheck blood pressure and target symptoms at 4 weeks and 8–12 weeks; repeat fasting glucose/HbA1c and lipids at ~3 months if those were baseline targets; sooner review if dizziness, bleeding signs, or glycemic symptoms appear

Qualitative Assessment

Leg heaviness, swelling perception, or evening edema in venous-prone users
Joint pain and morning stiffness
Exercise recovery and standing tolerance
Skin reactivity to sun (if photoprotection is a goal)
Ease of achieving target training without new dizziness

Pycnogenol for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment